ExpreS2ion to Present in Upcoming Investor Events
Hørsholm, Denmark, 12 September 2025 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce its participation in three key upcoming investor events in September 2025: Aktiespararna Aktiedagarna, the H.C. Andersen Capital Institutional Investor Seminar, and BioStock Investing in Life Science conference.
These events represent important opportunities to showcase ExpreS2ion’s innovative technology platform and exciting development pipeline to scientific and investment audiences. More details, including event registration information, are available on the Company’s website and via the links below. To arrange a meeting at these events, please contact us at investor@expres2ionbio.com.
16 September 2025 | Aktiespararna Aktiedagarna
Stockholm, Sweden
Join us for a live presentation from our CFO Keith Alexander on Tuesday, September 16th, at Aktiespararna’s Aktiedagarna in Stockholm. The event can be streamed through Aktiespararna’s YouTube channel or directly from their website. More information and registration can be found here: https://www.aktiespararna.se/aktiviteter/aktiedagarna-i-stockholm-55616
18 September 2025 | H.C. Andersen Institutional Investor Seminar
Copenhagen, Denmark
Join our CFO Keith Alexander on at HCA’s Institutional Seminar in Copenhagen. The event runs from 08:00 to 16:00 and is specially tailored for institutional investors, focusing on Danish equities. Please note that spaces are limited, and HCA reserves the right to decline registration in cases of overbooking. Secure your place through the following registration link: https://hca.videosync.fi/2025-09-18-investor-seminar/register
23 September 2025 | BioStock Investing in Life Science: From Seed to Success
Stockholm, Sweden
Join CFO Keith Alexander at BioStock’s “Investing in Life Science” event. Held from 09:00 to 17:00 at in Stockholm, this premier gathering unites forward-thinking investors and business leaders to explore transformative investments across early-, growth-, and late-stage life science ventures. To join us at this event, apply now for your free ticket—this is an invite-only event, and seats are limited. Registration is open via the BioStock event page: https://biostock.se/event/investing-in-life-science/
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.